Transcriptome-Guided Drug Repurposing for Aggressive SCCs

Roland Zauner* (Erstautor/-in), Monika Wimmer (Co-Autor/-in), Sonja Dorfer (Co-Autor/-in), Michael Ablinger (Co-Autor/-in), Ulrich Koller (Co-Autor/-in), Josefina Piñón Hofbauer (Co-Autor/-in), Christina Guttmann-Gruber (Co-Autor/-in), Johann Bauer (Co-Autor/-in), Verena Wally (Letztautor/-in)

*Korrespondierende/r Autor/-in für diese Arbeit

Publikation: Beitrag in FachzeitschriftOriginalarbeit (Zeitschrift)Begutachtung

3 Quellenangaben (Web of Science)

Abstract

Despite a significant rise in the incidence of cutaneous squamous cell carcinoma (SCC) in recent years, most SCCs are well treatable. However, against the background of pre-existing risk factors such as immunosuppression upon organ transplantation, or conditions such as recessive dystrophic epidermolysis bullosa (RDEB), SCCs arise more frequently and follow a particularly aggressive course. Notably, such SCC types display molecular similarities, despite their differing etiologies. We leveraged the similarities in transcriptomes between tumors from organ transplant recipients and RDEB-patients, augmented with data from more common head and neck (HN)-SCCs, to identify drugs that can be repurposed to treat these SCCs. The in silico approach used is based on the assumption that SCC-derived transcriptome profiles reflect critical tumor pathways that, if reversed towards healthy tissue, will attenuate the malignant phenotype. We determined tumor-specific signatures based on differentially expressed genes, which were then used to mine drug-perturbation data. By leveraging recent efforts in the systematic profiling and cataloguing of thousands of small molecule compounds, we identified drugs including selumetinib that specifically target key molecules within the MEK signaling cascade, representing candidates with the potential to be effective in the treatment of these rare and aggressive SCCs.
OriginalspracheEnglisch
FachzeitschriftINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Jahrgang23
Ausgabenummer2
DOIs
PublikationsstatusVeröffentlicht - 17 Jan. 2022

Fingerprint

Untersuchen Sie die Forschungsthemen von „Transcriptome-Guided Drug Repurposing for Aggressive SCCs“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren